AHCO — AdaptHealth Corp.

Summary of AdaptHealth (AHCO) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $819.8 million, up 5.4% year-over-year, exceeding guidance by approximately $22 million.
• Organic Growth: 9.1% year-over-year, with 500 basis points attributed to a new capitated contract.
• Adjusted EBITDA: $121.2 million, representing a margin of 14.8%, which was about $7 million below guidance due to elevated labor costs.
• Capitated Revenue: $74.9 million, contributing 9.2% to total revenue, with membership count increasing 7x year-over-year to approximately 15 million.
• Free Cash Flow: Negative $27.5 million, aligned with expectations, driven by capital expenditures of $121.2 million for new patient equipment.

2. Strategic Updates and Business Highlights

• Successfully transitioned hundreds of thousands of patients to a new capitated agreement, marking the largest patient transition in the home medical equipment industry.
• Established 35 new locations and became the exclusive HME provider for over 10 million new members.
• Significant investments in AI and digital platforms are improving operational metrics and patient experience, with 25% of scheduling now automated.
• The company is actively pursuing additional capitated arrangements, with promising discussions ongoing.

3. Forward Guidance and Outlook

• Full-Year Revenue Projection: Raised by $10 million to a range of $3.45 billion to $3.52 billion.
• Adjusted EBITDA Guidance: Maintained at $680 million to $730 million.
• Q2 Revenue Expectation: Projected between $840 million and $860 million, with an adjusted EBITDA margin of approximately 19%.
• Anticipated improvement in free cash flow in the second half of the year as capital expenditures normalize.

4. Bad News, Challenges, or Points of Concern

• Labor Costs: Elevated labor expenses of $12 million in Q1 due to the transition, which are expected to normalize by the end of Q2.
• Adjusted EBITDA Shortfall: The $7 million miss against guidance raises concerns about cost management during transitions.
• Wellness at Home Segment: Experienced a decline of 10.3% in revenue due to the disposal of non-core assets, although adjusted for these, it showed 11% organic growth.
• Increased Leverage: Net debt rose to approximately $1.84 billion, with a consolidated net leverage ratio of 3.0x, up from 2.75x in the previous quarter.

5. Notable Q&A Insights

• Organic Growth Breakdown: Core business growth (excluding capitated arrangements) was over 4%, indicating solid performance outside new contracts.
• Expectations for EBITDA: Anticipated ramp-up in EBITDA for Q2 due to a full quarter of capitated revenue and reduced labor costs.
• Capitated Contracts: The company is optimistic about new partnerships and sees a favorable trend in payer interest in capitated arrangements.
• Diabetes Segment: Positive growth attributed to improved execution rather than market changes; ongoing evaluation of strategic fit within the portfolio.

Overall, AdaptHealth's Q1 2026 results reflect strong revenue growth and strategic advancements, particularly in capitated contracts, but are tempered by elevated labor costs and challenges in certain segments. The company remains optimistic about future growth and operational improvements.